ZA200903903B - Crystalline solid rasagiline base - Google Patents
Crystalline solid rasagiline baseInfo
- Publication number
- ZA200903903B ZA200903903B ZA200903903A ZA200903903A ZA200903903B ZA 200903903 B ZA200903903 B ZA 200903903B ZA 200903903 A ZA200903903 A ZA 200903903A ZA 200903903 A ZA200903903 A ZA 200903903A ZA 200903903 B ZA200903903 B ZA 200903903B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline solid
- rasagiline base
- solid rasagiline
- base
- aminoindan
- Prior art date
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
- 229960000245 rasagiline Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87501106P | 2006-12-14 | 2006-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200903903B true ZA200903903B (en) | 2010-08-25 |
Family
ID=39536623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200903903A ZA200903903B (en) | 2006-12-14 | 2007-12-13 | Crystalline solid rasagiline base |
Country Status (25)
Country | Link |
---|---|
US (4) | US7750051B2 (xx) |
EP (1) | EP2101569B1 (xx) |
JP (1) | JP5623081B2 (xx) |
KR (1) | KR101459744B1 (xx) |
CN (1) | CN101557706B (xx) |
AT (1) | ATE528989T1 (xx) |
AU (1) | AU2007334428B2 (xx) |
CA (1) | CA2672414A1 (xx) |
CY (1) | CY1112511T1 (xx) |
DK (1) | DK2101569T3 (xx) |
EA (1) | EA016820B1 (xx) |
ES (1) | ES2375761T3 (xx) |
HK (1) | HK1129276A1 (xx) |
HR (1) | HRP20110980T1 (xx) |
IL (1) | IL198985A0 (xx) |
MX (1) | MX2009006251A (xx) |
NO (1) | NO20092611L (xx) |
NZ (1) | NZ577460A (xx) |
PL (1) | PL2101569T3 (xx) |
PT (1) | PT2101569E (xx) |
RS (1) | RS52183B (xx) |
SI (1) | SI2101569T1 (xx) |
UA (1) | UA97502C2 (xx) |
WO (1) | WO2008076348A1 (xx) |
ZA (1) | ZA200903903B (xx) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507586A (ja) * | 2004-07-26 | 2008-03-13 | テバ ファーマシューティカル インダストリーズ リミティド | ラサグリンを含む、医薬投与剤 |
CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
PL1848415T3 (pl) * | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
NZ560660A (en) | 2005-02-23 | 2010-11-26 | Teva Pharma | Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity |
CA2630037C (en) * | 2005-11-17 | 2015-03-31 | Teva Pharmaceutical Industries Ltd. | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
ES2375761T3 (es) * | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | Base de rasagilina cristalina sólida. |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
WO2009147430A1 (en) | 2008-06-02 | 2009-12-10 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
JP2011524907A (ja) * | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
AU2009260733B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
CN101606923B (zh) * | 2008-06-20 | 2013-01-09 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
ITMI20081406A1 (it) * | 2008-07-29 | 2010-01-30 | Dipharma Francis Srl | Forma cristallina di rasagilina e procedimento per la sua preparazione |
EP2657221A1 (en) | 2008-11-20 | 2013-10-30 | Dr. Reddy's Laboratories Ltd. | Preparation of rasagiline and salts thereof |
EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
RS53504B1 (en) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | RAZAGILIN SALTS AND THEIR PHARMACEUTICAL PREPARATIONS |
EP2298277A1 (en) * | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
CN102048717B (zh) | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
WO2011121607A2 (en) | 2010-03-29 | 2011-10-06 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
UA103851C2 (xx) | 2010-04-30 | 2013-11-25 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Трансдермальна композиція на основі пропіламіноіндану$трансдерамальная композиция на основе пропиламиноиндана |
JP2013533287A (ja) | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
US8691872B2 (en) | 2010-07-27 | 2014-04-08 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
WO2012153349A2 (en) | 2011-05-04 | 2012-11-15 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
EP2766004A4 (en) | 2011-10-10 | 2015-04-22 | Teva Pharma | R (+) - N-methyl-propargyl-aminoindan |
EA201490761A1 (ru) | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
EP2610239A1 (en) | 2012-01-02 | 2013-07-03 | Dr. Reddy's Laboratories Ltd. | Preparation Of Rasagiline Hemitartrate |
ES2584059T3 (es) | 2012-03-21 | 2016-09-23 | Synthon Bv | Composiciones farmacéuticas estabilizadas que comprenden sales de rasagilina |
EP2884972A4 (en) | 2012-08-17 | 2016-05-11 | Teva Pharma | PARENTERAL FORMULATION OF RASAGILINE |
WO2014070622A1 (en) | 2012-11-02 | 2014-05-08 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
US4529811A (en) * | 1981-03-02 | 1985-07-16 | G. D. Searle & Co. | Process for isolating organic compounds and lithium salt complexes useful in said process |
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
IL112819A (en) | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
CN1166622C (zh) | 1995-02-01 | 2004-09-15 | 法玛西雅厄普约翰美国公司 | 作为选择性多巴胺d3配体的2-氨基-1,2-二氢化茚 |
IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
US5663415A (en) | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
DK0966435T3 (da) | 1996-12-18 | 2005-08-15 | Teva Pharma | Aminoindanderivater |
US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
CA2319318A1 (en) | 1998-01-27 | 1999-07-29 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
IL141690A (en) | 2001-02-27 | 2004-06-20 | Isp Finetech Ltd | Process for preparation of rasagiline and its salts |
US6543155B2 (en) * | 2001-03-01 | 2003-04-08 | National Agricultural Research Organization | Freeze-dried product and process and apparatus for producing it |
EP1441708B1 (en) * | 2001-11-05 | 2009-04-08 | Krele Pharmaceuticals LLC | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
UA78854C2 (en) | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
US7396860B2 (en) | 2002-11-15 | 2008-07-08 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20040157784A1 (en) | 2003-02-10 | 2004-08-12 | Jame Fine Chemicals, Inc. | Opiod tannate compositions |
JP5460947B2 (ja) | 2003-09-03 | 2014-04-02 | グラクソ グループ リミテッド | 新規調製方法、塩、組成物及び使用 |
US7799273B2 (en) * | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
JP2008507586A (ja) | 2004-07-26 | 2008-03-13 | テバ ファーマシューティカル インダストリーズ リミティド | ラサグリンを含む、医薬投与剤 |
CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
RU2389482C2 (ru) | 2004-11-24 | 2010-05-20 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина, распадающиеся в ротовой полости |
NZ560660A (en) * | 2005-02-23 | 2010-11-26 | Teva Pharma | Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity |
CA2630037C (en) * | 2005-11-17 | 2015-03-31 | Teva Pharmaceutical Industries Ltd. | Methods for isolating propargylated aminoindans |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
CN101032474B (zh) | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
US7573834B2 (en) * | 2006-05-31 | 2009-08-11 | Alcatel Lucent | Method and system for allocating a group bit rate among multiple bonded pairs in a communications network |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
JP5356248B2 (ja) | 2006-12-14 | 2013-12-04 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンのタンニン酸塩 |
ES2375761T3 (es) | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | Base de rasagilina cristalina sólida. |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
US20090062400A1 (en) | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
EP2234478A4 (en) | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
US20110117200A1 (en) | 2008-03-31 | 2011-05-19 | Actavis Group Ptc Ehf | Rasagiline mesylate particles and process for the preparation thereof |
US20100008983A1 (en) | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
AU2009260733B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
JP2011524907A (ja) * | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
RS53504B1 (en) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | RAZAGILIN SALTS AND THEIR PHARMACEUTICAL PREPARATIONS |
WO2011042812A1 (en) | 2009-10-09 | 2011-04-14 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
WO2011087791A1 (en) | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
JP2013533287A (ja) | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
US8691872B2 (en) * | 2010-07-27 | 2014-04-08 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
US20120101168A1 (en) | 2010-10-26 | 2012-04-26 | Eliezer Bahar | Deuterium enriched rasagiline |
AU2012323346A1 (en) * | 2011-10-10 | 2014-05-15 | Teva Pharmaceutical Industries Ltd | Rasagiline citramide |
EP2766004A4 (en) * | 2011-10-10 | 2015-04-22 | Teva Pharma | R (+) - N-methyl-propargyl-aminoindan |
EA201490761A1 (ru) * | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
-
2007
- 2007-12-13 ES ES07862906T patent/ES2375761T3/es active Active
- 2007-12-13 UA UAA200906360A patent/UA97502C2/ru unknown
- 2007-12-13 MX MX2009006251A patent/MX2009006251A/es active IP Right Grant
- 2007-12-13 KR KR1020097014006A patent/KR101459744B1/ko not_active IP Right Cessation
- 2007-12-13 RS RS20120016A patent/RS52183B/en unknown
- 2007-12-13 CN CN2007800458662A patent/CN101557706B/zh not_active Expired - Fee Related
- 2007-12-13 WO PCT/US2007/025583 patent/WO2008076348A1/en active Application Filing
- 2007-12-13 EA EA200970581A patent/EA016820B1/ru not_active IP Right Cessation
- 2007-12-13 NZ NZ577460A patent/NZ577460A/en unknown
- 2007-12-13 SI SI200730807T patent/SI2101569T1/sl unknown
- 2007-12-13 ZA ZA200903903A patent/ZA200903903B/xx unknown
- 2007-12-13 CA CA002672414A patent/CA2672414A1/en not_active Abandoned
- 2007-12-13 AU AU2007334428A patent/AU2007334428B2/en not_active Ceased
- 2007-12-13 PT PT07862906T patent/PT2101569E/pt unknown
- 2007-12-13 EP EP07862906A patent/EP2101569B1/en active Active
- 2007-12-13 DK DK07862906.0T patent/DK2101569T3/da active
- 2007-12-13 JP JP2009541390A patent/JP5623081B2/ja not_active Expired - Fee Related
- 2007-12-13 PL PL07862906T patent/PL2101569T3/pl unknown
- 2007-12-13 AT AT07862906T patent/ATE528989T1/de active
- 2007-12-13 US US12/002,082 patent/US7750051B2/en not_active Expired - Fee Related
-
2009
- 2009-05-27 IL IL198985A patent/IL198985A0/en unknown
- 2009-07-08 NO NO20092611A patent/NO20092611L/no not_active Application Discontinuation
- 2009-10-13 HK HK09109428.4A patent/HK1129276A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 US US12/655,828 patent/US20100144887A1/en not_active Abandoned
- 2010-01-08 US US12/655,827 patent/US8614252B2/en not_active Expired - Fee Related
-
2011
- 2011-12-29 HR HR20110980T patent/HRP20110980T1/hr unknown
-
2012
- 2012-01-11 CY CY20121100022T patent/CY1112511T1/el unknown
-
2014
- 2014-08-14 US US14/459,877 patent/US20150038744A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200903903B (en) | Crystalline solid rasagiline base | |
HK1129277A1 (en) | Tannate salt of rasagiline | |
MX2010002974A (es) | Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida. | |
MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
PH12015500550A1 (en) | Anti-notch1 nrr antibodies and methods using same | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
WO2007019439A3 (en) | Block copolymer compositions and uses thereof | |
TW200716512A (en) | Processes for preparing cinacalcet hydrochloride crystal form I | |
TW200608973A (en) | Rapamycin polymorph Ⅱ and uses thereof | |
WO2007127841A3 (en) | Compositions and methods of preparation thereof | |
HK1124548A1 (en) | Human anti-il-23 antibodies, compositions, methods and uses il-23 | |
EP2151461A3 (en) | Benzylated polyalkylene polyamines and uses thereof | |
MY148286A (en) | Freeze-dried, aerated dairy or dairy-substitute compositions and methods of making thereof | |
IL175512A0 (en) | Methods of preparing aripiprazole crystalline forms | |
WO2009067674A3 (en) | Polymorphs of sunitinib base and processes for preparation thereof | |
WO2008057291A3 (en) | Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof | |
TW200738649A (en) | Calcilytic compounds | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
EP2644614A3 (en) | Solid state forms of 5-azacytidine and processes for preparation thereof | |
WO2006091836A8 (en) | Formulations of ladostigil tartrate | |
TW200638932A (en) | CCI-779 polymorph and use thereof | |
TW200637804A (en) | Substantially pure tolterodine tartrate and process for preparing thereof | |
WO2008015584A3 (en) | Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof | |
WO2009025792A3 (en) | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof | |
EP1991248A4 (en) | ANTIDEPRESSANT PRODRUGS |